Abstract #0809

Hyperpolarized 13C MRSI monitoring of response to HDAC inhibition in glioblastoma

Marina Radoul¹, Myriam M. Chaumeil², Pia Eriksson¹, Chloe Najac¹, Pavithra Viswanath¹, Mark Kelly³, Anne Marie Gillespie¹, Joydeep Mukherjee⁴, Russell O. Pieper⁴, and Sabrina M. Ronen¹

¹Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States, ²Physical Therapy and Rehabilitation Science/Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States, ³Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, United States, ⁴Neurological Surgery, University of California San Francisco, San Francisco, CA, United States

Treatment of glioblastoma (GBM) is comprised of maximum safe surgical resection, radiotherapy and chemotherapy with Temozolomide. Nonetheless, the median survival of GBM patients is only 15 months with five-year survival rate of only 5.5%. Vorinostat, the clinically relevant histone deacetylase (HDAC) inhibitor, is a novel drug that inhibits cell proliferation and induces apoptosis in solid tumors. Following Vorinostat treatment, we show a significant decrease in hyperpolarized [1-¹³C] lactate-to-pyruvate ratio that was associated with enhanced survival of glioblastoma-bearing mice. This highlights the potential of hyperpolarized ¹³C MRSI for monitoring response to a type of anticancer therapy previously unexplored in GBM patients.

This abstract and the presentation materials are available to members only; a login is required.

Join Here